Advancing discoveries to beat cancer. Cancer Research Technology (CRT) is a specialist commercialisation and development company. Owned by Cancer Research UK, the world’s leading cancer charity, CRT has exclusive rights to intellectual property from Cancer Research UK funded research – more than £300M annually. CRT has 3 marketed drugs and over 30 partnered agents in preclinical and clinical development. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. Working closely with leading international cancer scientists, CRT establishes links with commercial partners or provides translational resources either in the academic institution or through CRT’s internal Discovery Laboratories. Our Clinical Development Partnerships (CDP) initiative targets leading biotechnology and pharmaceutical companies that have de-prioritised clinical agents. CDP seeks to sponsor, manage and support early-stage clinical trials bringing new life to these de-prioritised or under-resourced anti-cancer agents. To date, 8 agents have been adopted under the CDP’s innovative model with 4 projects in Phase 1. CRT has opportunities available for licensing or co-development. For more information, visit www.cancertechnology.com